Regulatory T-cells and effects of anti-CTLA4 and anti-PD1 therapy in a transgenic murine model of neuroblastoma

被引：0

作者：

Chan, Randall ^{[1
]}

Shirinbak, Soheila ^{[1
]}

Muthugounder, Sakunthala ^{[1
]}

Hung, Long ^{[1
]}

Gnanachandran, Janahan ^{[1
]}

Hajidaniel, Michael ^{[1
]}

Asgharzadeh, Shahab ^{[1
]}

机构：

[1] USC Childrens Hosp Los Angeles, Los Angeles, CA USA

来源：

CANCER RESEARCH | 2014年 / 74卷 / 19期

关键词：

D O I：

10.1158/1538-7445.AM2014-5021

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5021

引用

页数：2

共 50 条

[21] Anti-CTLA-4 generates memory T-cells with greater expansion and functionality than anti-PD-1
Mok, Stephen
Liu, Huey
Anang, Nana-Ama A. S.
Mancuso, James J.
Cobanoglu, Didem Agac
Allison, James P.
CANCER RESEARCH, 2024, 84 (06)
[22] Cyclophosphamide depletes tumor infiltrating T regulatory cells and combined with anti-PD-1 therapy improves survival in murine neuroblastoma
Webb, Emily R.
Moreno-Vincente, Julia
Easton, Alistair
Lanati, Silvia
Taylor, Martin
James, Sonya
Williams, Emily L.
English, Vikki
Penfold, Chris
Beers, Stephen A.
Gray, Juliet C.
ISCIENCE, 2022, 25 (09)
[23] Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in metastatic NSCLC patients: The RECLAIM study
Bahce, I.
Schneiders, F. L.
Hashemi, S.
Veltman, J.
Daniels, H.
Fransen, M.
Radonic, T.
Ulas, E.
Houda, I.
Barlo, N.
Disselhorst, M.
van Laren, M.
Tiemessen, M.
Tarasevych, S.
van Haarst, J. M. M.
van Tilburg, P.
Kunst, P.
Moons-Pasic, A.
de Gruijl, T. D.
Senan, S.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1021 - S1021
[24] Tumor eradication in a murine model of glioma with vaccination and anti-CTLA-4 but not anti-PD-1
Field, Cameron S.
Hunn, Martin K.
Ferguson, Peter M.
Yagita, Hideo
Hermans, Ian F.
Ancelet, Lindsay R.
CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
[25] Effect of radiofrequency ablation (RFA) combined with anti-CTLA-4 and anti-PD1 in a preclinical melanoma model.
Franco-Mahecha, Olga L.
Christou, Anna
Mauda-Havakuk, Michal
Katti, Prateek
Pritchard, William F.
Karanian, John W.
Wood, Bradford J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
[26] Combination between a long-acting engineered cytokine (NKTR-214) and checkpoint inhibitors anti-CTLA4 or anti-PD1 in inurine tumor models
Kantak, Seema S.
Lee, Steve
Addepalli, Murali
Hoch, Ute
Penax, Rhoneil
Pena, Rhoneil
Kirksey, Yolanda
Charych, Deborah H.
Doberstein, Stephen K.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[27] Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit
Patel, Anisha B.
Farooq, Sahira
Welborn, Macartney
Amaria, Rodabe N.
Chon, Susan Y.
Diab, Adi
Oliva, Isabella C. Glitza
Huen, Auris O.
Li, Shirley Q.
Nelson, Kelly C.
Pacha, Omar
Patel, Sapna P.
Rapini, Ronald P.
Tawbi, Hussein A.
Wong, Michael K.
McQuade, Jennifer
Davies, Michael A.
Haydu, Lauren E.
CANCER, 2022, 128 (05) : 975 - 983
[28] Early T Cell Infiltration Correlates with Anti-CTLA4 Treatment Response in Murine Cancer Models
Almonte, Andrew A.
Cavic, George
Carroll, Christina S. E.
Neeman, Teresa
Fahrer, Aude M.
JOURNAL OF IMMUNOLOGY, 2023, 211 (12): : 1858 - 1867
[29] Durable remissions associated with anti-CTLA-4 and anti-PD1 checkpoint inhibitors in a single center
Smit, T.
Rapoport, B. L.
Van Eeden, R. I.
ANNALS OF ONCOLOGY, 2017, 28
[30] Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response
Rupp, Tristan
Genest, Laurie
Babin, David
Legrand, Christophe
Hunault, Marion
Froget, Guillaume
Castagne, Vincent
TRANSLATIONAL ONCOLOGY, 2022, 20

← 1 2 3 4 5 →